7-day free trial: Get unlimited comparisons, and stock, ETF and mutual fund analyses for just $14.95 a month, without ads. Start a free trial. Go ad free!

Cara Therapeutics, Inc. (CARA) Stock Guide

September 17, 2020
71
Bull Case
  • Revenue growth higher than the industry and sector averages
  • Company’s profitability is improving
  • Buy analyst rating
  • Average analyst stock price above current stock price
  • Cash/Debt ratio is higher than the industry and sector averages
Bear Case
  • High short share of float
  • High short interest

Before we start: if you're looking for CARA stock price, you can quickly find it out by visiting Finny and typing "CARA quote". If you're looking for a quick scoop on CARA stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "CARA". You'll get all this info in one place. Or you can just type "CARA news" to get the latest stock news.

Looking to buy or sell Cara Therapeutics, Inc. (CARA)? Interested in getting the full scoop on CARA, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this CARA stock guide, we'll address key questions about CARA, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are CARA earnings?
2. What is CARA stock forecast (i.e., prediction)?
3. CARA buy or sell? What is CARA Finny Score?
4. What are the reasons to buy CARA? Why should I buy CARA stock?
5. What are the reasons to sell CARA? Why should I sell CARA stock?
6. What are CARA key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are CARA earnings?

CARA trailing 12-month earnings per share (EPS) is -$2.50.

Analyst Predictions

2. What is CARA stock forecast (i.e., prediction)?

Based on CARA analyst price targets, CARA stock forecast is $33.25 (for a year from now). That means the average analyst price target for CARA stock is $33.25. The prediction is based on 7 analyst estimates.

The low price target for CARA is $20.00, while the high price target is $40.00.

CARA analyst rating is Buy.

Analysis

3. CARA buy or sell? What is CARA Finny Score?

Our quantitative analysis shows 5 reasons to buy and 2 reasons to sell CARA, resulting in Finny Score of 71.

4. What are the reasons to buy CARA? Why should I buy CARA stock?

Here are the reasons to buy CARA stock:

5. What are the reasons to sell CARA? Why should I sell CARA stock?

Let's look at the reasons to sell CARA stock (i.e., the bear case):

  • CARA short share of float is 8.90%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock. See CARA short share of float chart.
  • CARA short interest (days to cover the shorts) ratio is 10.44. The stock garners more short interest than the average industry, sector or S&P 500 stock. See CARA short interest ratio chart.

Key Stats

6. What are CARA key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for CARA:

Metrics CARA
Price $12.72
Average Price Target / Upside $33.25 / 161.30%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 55
Market Cap $707.05M
Forward P/E Ratio -6.39
Price/Book Ratio 29.43
Revenue (TTM) $24.02M
YoY Quarterly Revenue Growth 8.20%
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us